Michael Amoroso Sells 36,838 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the completion of the transaction, the chief executive officer now owns 107,087 shares in the company, valued at approximately $500,096.29. This represents a 25.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The shares were sold at an average price of $8.19, for a total value of $24,668.28.

Precision BioSciences Price Performance

Shares of DTIL opened at $5.00 on Friday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 1 year low of $3.61 and a 1 year high of $19.43. The stock has a market cap of $38.35 million, a P/E ratio of 83.35 and a beta of 1.51. The stock’s 50-day moving average price is $5.56 and its two-hundred day moving average price is $8.01.

Hedge Funds Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC grew its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,974 shares of the company’s stock after buying an additional 19,088 shares during the period. Geode Capital Management LLC owned approximately 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities and Exchange Commission. 37.99% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DTIL shares. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a report on Friday, January 10th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.